Centauri Therapeutics Overview
- Founded
-
2014

- Status
-
Private
- Employees
-
7

- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$32.5M
- Investors
-
9
Centauri Therapeutics General Information
Description
Operator of a biotechnology company intended to discover and develop novel molecules and immunotherapy targeting life-threatening diseases. The company uses alphamer technology, in which chemically synthesized molecules redirect naturally occurring antibodies to selected pathogens to fight infections, enabling doctors to treat infectious diseases efficiently.
Contact Information
Website
www.centauritherapeutics.com
Formerly Known As
Altermet, Altermune
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- Discovery Park
- Kent CT13 9ND
- England, United Kingdom
+44 01304 000000
Centauri Therapeutics Timeline
Centauri Therapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
6. Later Stage VC (Series A) | 16-Feb-2022 | $32.5M | 000.00 | Completed | Generating Revenue | |
5. Later Stage VC | 14-Aug-2020 | 00000 | 00.00 | 000.00 | Completed | Generating Revenue |
4. Early Stage VC | 01-Dec-2018 | 00.000 | 00.000 | 000.00 | Completed | Generating Revenue |
3. Accelerator/Incubator | 11-Sep-2017 | 00.000 | 00.000 | Completed | Generating Revenue | |
2. Early Stage VC | 20-Feb-2017 | $3.13M | $6.11M | Completed | Generating Revenue | |
1. Early Stage VC | 21-Dec-2016 | $2.99M | $2.99M | 000.00 | Completed | Startup |
Centauri Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Ordinary | 0,000 | 00.000000 | 0000.00 | 0000.00 | 0000.00 | 0.000 | ||
Ordinary | 0,000 | 00.000000 | 0000.00 | 0000.00 | 0000.00 | 0.000 | ||
Ordinary | 000 | 00.000000 | 0000.00 | 0000.00 | 0000.00 | 0.00 | ||
Ordinary | 0,000 | 00.000000 | 0000.00 | 0000.00 | 0000.00 | 0.00 | ||
Ordinary | 0,000 | 00.000000 | 0000.00 | 0000.00 | 0000.00 | 00.000 | ||
Ordinary | 000 | 00.000000 | 0000.00 | 0000.00 | 0000.00 | 0.000 | ||
Ordinary | 00 | 00.000000 | 0000.00 | 0000.00 | 0000.00 | 0.000 | ||
Ordinary | 000 | 00.000000 | 0000.00 | 0000.00 | 0000.00 | 0.000 | ||
Ordinary | 621 | $0.003110 | $311.57 | $311.57 | $311.57 | 1.04% | ||
Ordinary | 311 | $0.003110 | $311.07 | $311.07 | $311.07 | 0.52% |
Centauri Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a biotechnology company intended to discover and develop novel molecules and immunotherapy targeting life-th
Drug Discovery
Kent, United Kingdom
7
As of 2022
000.00
00000000000
000.00
Centauri Therapeutics Competitors (21)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Light Chain Bioscience | Private Equity-Backed | Geneva, Switzerland | 00 | 00000 | 00000000000 | 00000 |
00000000 | Venture Capital-Backed | Vienna, Austria | 00.000 | 0000000000 | 00.000 | |
0000000 0000000000 | Formerly VC-backed | Boston, MA | 0 | 00000 | 000000000 | 00000 |
0000000 | Venture Capital-Backed | Oxford, United Kingdom | 00 | 00000 | 00000000000 | 00000 |
000000 | Venture Capital-Backed | Cambridge, United Kingdom | 00 | 00000 | 00000000000 | 00000 |
Centauri Therapeutics Patents
Centauri Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
GB-201804098-D0 | Novel compounds and therapeutic uses thereof | Ceased | 14-Mar-2018 | 000000000 | |
AU-2019233810-A1 | Immunity linker molecules and their use in the treatment of infectious diseases | Pending | 14-Mar-2018 | 0000000000 | |
EP-3765155-A1 | Immunity linker molecules and their use in the treatment of infectious diseases | Pending | 14-Mar-2018 | 0000000000 | |
US-20210085798-A1 | Immunity linker molecules and their use in the treatment of infectious diseases | Pending | 14-Mar-2018 | 0000000000 | |
GB-201707079-D0 | Novel compounds and therapeutics uses thereof | Ceased | 04-May-2017 | A61K38/12 |
Centauri Therapeutics Executive Team (2)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Michael Westby Ph.D | Chief Scientific Officer & Board Member | ||
Stuart Lawson | Co-Founder, Chief Financial Officer & Board Member |
Centauri Therapeutics Board Members (8)
Name | Representing | Role | Since |
---|---|---|---|
Camilla Hansen Ph.D | Novo Holdings | Board Member | 000 0000 |
Johannes Zanzinger Ph.D | Boehringer Ingelheim Venture Fund | Board Member | 000 0000 |
Jonathan Synett | NCL Technology Ventures | Board Member | 000 0000 |
Karen Lackey | Evotec | Board Member | 000 0000 |
Michael Westby Ph.D | Centauri Therapeutics | Chief Scientific Officer & Board Member | 000 0000 |
Centauri Therapeutics Signals
Centauri Therapeutics Investors (9)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Boehringer Ingelheim Venture Fund | Venture Capital | Minority | 000 0000 | 000000 0 | |
Evotec | Corporation | Minority | 000 0000 | 000000 0 | |
Novo Holdings | Venture Capital | Minority | 000 0000 | 000000 0 | |
Wren Capital | Angel Group | Minority | 000 0000 | 000000 0 | |
Innovate UK | Government | 000 0000 | 000000 0 |
Centauri Therapeutics Investments (2)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
00000000 0000 | 02-Mar-2016 | 00000 0000 | 00000 | Drug Discovery | 0000000 0 |
Altermune Technologies | 18-Jan-2016 | Buyout/LBO | Drug Discovery | 0000000 0 |